Register online | Log in | My Prescrire

Issue contents

• Current issue
• Last 12 issues
• All issues

Topics

• Annual Prescrire Awards
• Advancing healthcare policy
• Positions
• Mediator° - the criminal trial
• Drugs to avoid: 2021 update
• Spotlight

About Prescrire

• Who are we?
• How we work
• AMP: non-profit
• Financing
• No conflicts of interest
• Where to find us
• About Prescrire International
• Testimonials
• Prescrire events
• A global network

Offers

• Subscribe now
• Solidarity Subscription Rate
• Subscribers: register online
• Prescrire's other products
• Free Special Edition
• Sign up to receive the newsletter

Prescrire's other websites

In Prescrire's Spotlight

A critical eye  Editorial  Welcome to the new, redesigned Prescrire International: a "critical eye" on drugs in Europe, with patients' interests front and centre. 1 January 2022

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Crizanlizumab (Adakveo°) to prevent vaso-occlusive crises in sickle-cell disease: No proven clinical advantages FEATURED REVIEW Is crizanlizumab more effective than hydroxycarbamide for patients with sickle-cell disease? Does it prevent vaso-occlusive crises and their serious complications when hydroxycarbamide is not sufficiently effective or cannot be used? What is its adverse effect profile? Full review (5 pages) available for download by subscribers. 1 January 2022

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ In the January issue of Prescrire International: adverse effects of lamotrigine and biotin FREE DOWNLOAD In our sample page from this month's issue, cardiac arrhythmias with lamotrigine, and biotin supplements' interference with laboratory tests. Full text available for free download. 1 January 2022

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Dravet syndrome: fenfluramine (Fintepla°) for children is unacceptable Giving fenfluramine to children with Dravet syndrome (a rare and severe form of epilepsy), including those whose seizures remain frequent despite optimised treatment, increases the incidence of the most serious seizures and exposes them to a risk of serious cardiovascular adverse effects. 1 January 2022

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Vitamin D drops for infants: mistakes to avoid Errors and accidents are frequent with vitamin D supplied in dropper bottles. These include handling by children, eye exposure and, above all, overdose due to a mistake or related to a defective dropper bottle. 1 January 2022

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Alzheimer's: yet another unwelcome drug Despite aducanumab's lack of demonstrated efficacy in Alzheimer's disease, the scene is set to raise the hopes of patients and those close to them, and above all to promote the interests of the company and its shareholders. 1 January 2022

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Enjoy these features, and more, in our upcoming issues COMING SOON Drugs to avoid in 2022 • Combinations containing sofosbuvir in chronic hepatitis C • Olaparib and ovarian cancer • Update on myocarditis linked to covid-19 messenger RNA vaccines • Pneumococcal vaccine errors in infants... > Subscribe now 1 January 2022

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Covid-19 : Follow Prescrire's independent, evidence-based analysis of the pandemic  COVID-19  Prescrire's editors are publishing an ongoing series of articles featuring independent analysis of developments related to the covid-19 pandemic. Useful and practical information, to help healthcare professionals gain a clear and balanced view. 1 January 2022

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Subscribe today for full access to top-quality content from Prescrire International  SUBSCRIBE NOW!  Enjoy access to subscriber-only content available on our website, including every article published in Prescrire International since 1992. Prices for a one-year subscription start at 150 euros (less for students and residents of lower-income countries). 1 January 2022

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Follow Prescrire International on Facebook and Twitter Keep up with the latest from Prescrire's editors, and support our values of independence and quality information, first and foremost in the interest of patients. Click here to > Follow us on Facebook or > Follow us on Twitter 1 January 2022

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ "Top Texts of 2021", from the editors of Prescrire International  FREE SPECIAL EDITION  Check out this sampling of texts from Prescrire International, a wholly independent monthly drug bulletin, written by and for healthcare professionals. Inside, top articles from sections dedicated to new drugs authorised in Europe and updates on adverse drug effects, plus our annual update of drugs to avoid. > Click here for your free copy 1 January 2022

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Receive the free, monthly "Independent Drug & Healthcare Newsletter" Click here to sign up for the free Newsletter from the editors of the non-profit journal Prescrire International, with highlights of the contents of the latest issue. 1 January 2022

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Drugs to avoid, in the name of better patient care   DRUGS TO AVOID - 2021 UPDATE  Independent French medical journal Prescrire has published its annual update of drugs to avoid. The goal is to make it easier to choose high-quality care, and to prevent disproportionate harm to patients. > Read more

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Read more All the subjects in Prescrire's Spotlight >

• Sitemap |
• Terms of use |
• Contact
• |Top of page